Effie W Petersdorf1, Mary Carrington2, Colm O'hUigin3, Mats Bengtsson4, Dianne De Santis5, Valerie Dubois6, Ted Gooley7, Mary Horowitz8, Katharine Hsu9, J Alejandro Madrigal10, Martin J Maiers11, Mari Malkki7, Caroline McKallor7, Yasuo Morishima12, Machteld Oudshoorn13, Stephen R Spellman11, Jean Villard14, Phil Stevenson7. 1. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: epetersd@fredhutch.org. 2. Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. 3. Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 4. Department of Immunology, Genetics and Pathology, University of Uppsala, Uppsala, Sweden. 5. PathWest, Fiona Stanley Hospital, Perth, WA, Australia. 6. Etablissement Français du Sang Auvergne Rhône Alpes, site de Lyon, Décines, France. 7. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 8. Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. 9. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10. Anthony Nolan Research Institute, Royal Free Hospital, London, UK. 11. Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA. 12. Aichi Medical University School of Medicine, Nagakute, Aichi, Japan. 13. Leiden University Medical Centre, Department Immunohematology and Blood Transfusion, Leiden, Netherlands; Matchis Foundation, Leiden, Netherlands. 14. Geneva University Hospital, Geneva, Switzerland.
Abstract
BACKGROUND: The success of unrelated haemopoietic cell transplantation (HCT) is limited by graft-versus-host disease (GVHD), which is the main post-transplantation challenge when HLA-matched donors are unavailable. A sequence dimorphism in exon 1 of HLA-B gives rise to leader peptides containing methionine (Met; M) or threonine (Thr; T), which differentially influence natural killer and T-cell alloresponses. The main aim of the study was to evaluate the role of the leader dimorphism in GVHD after HLA-B-mismatched unrelated HCT. METHODS: We did a retrospective cohort study of 33 982 patients who received an unrelated HCT done in Australia, Europe, Japan, North America, and the UK between Jan 1, 1988, and Dec 31, 2016. Data were contributed by participants of the International Histocompatibility Working Group in Hematopoietic Cell Transplantation. All cases were included and there were no exclusion criteria. Multivariate regression models were used to assess risks associated with HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 mismatching. Among the 33 982 transplantations, the risks of GVHD associated with HLA-B M and T leaders were established in 17 100 (50·3%) HLA-matched and 1457 (4·3%) single HLA-B-mismatched transplantations using multivariate regression models. Leader frequencies were defined in 2 004 742 BeTheMatch US registry donors. FINDINGS: Between Jan 20, 2017, and March 11, 2019, we assessed 33 982 HCTs using multivariate regression models for the role of HLA mismatching on outcome. Median follow-up was 1841 days (IQR 909-2963). Mortality and GVHD increased with increasing numbers of HLA mismatches. A single HLA-B mismatch increased grade 3-4 acute GVHD (odds ratio [OR] 1·89, 95% CI 1·53-2·33; p<0·0001). Among the single HLA-B-mismatched transplantations, acute GVHD risk was higher with leader mismatching than with leader matching (OR 1·73, 1·02-2·94; p=0·042 for grade 2-4) and with an M leader shared allotype compared with a T leader shared allotype (OR 1·98, 1·39-2·81; p=0·0001 for grade 3-4). The preferred HLA-B-mismatched donor is leader-matched and shares a T leader allotype. The majority (1 836 939 [91·6%]) of the 2 004 742 US registry donors have the TT or MT genotype. INTERPRETATION: The HLA-B leader informs GVHD risk after HLA-B-mismatched unrelated HCT and differentiates high-risk HLA-B mismatches from those with lower risk. The leader of the matched allotype could be considered to be as important as the leader of the mismatched allotype for GVHD. Prospective identification of leader-matched donors is feasible for most patients in need of a HCT, and could lower GVHD and increase availability of HCT therapy. These findings are being independently validated and warrant further research in prospective trials. FUNDING: The National Institutes of Health, USA.
BACKGROUND: The success of unrelated haemopoietic cell transplantation (HCT) is limited by graft-versus-host disease (GVHD), which is the main post-transplantation challenge when HLA-matched donors are unavailable. A sequence dimorphism in exon 1 of HLA-B gives rise to leader peptides containing methionine (Met; M) or threonine (Thr; T), which differentially influence natural killer and T-cell alloresponses. The main aim of the study was to evaluate the role of the leader dimorphism in GVHD after HLA-B-mismatched unrelated HCT. METHODS: We did a retrospective cohort study of 33 982 patients who received an unrelated HCT done in Australia, Europe, Japan, North America, and the UK between Jan 1, 1988, and Dec 31, 2016. Data were contributed by participants of the International Histocompatibility Working Group in Hematopoietic Cell Transplantation. All cases were included and there were no exclusion criteria. Multivariate regression models were used to assess risks associated with HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 mismatching. Among the 33 982 transplantations, the risks of GVHD associated with HLA-B M and T leaders were established in 17 100 (50·3%) HLA-matched and 1457 (4·3%) single HLA-B-mismatched transplantations using multivariate regression models. Leader frequencies were defined in 2 004 742 BeTheMatch US registry donors. FINDINGS: Between Jan 20, 2017, and March 11, 2019, we assessed 33 982 HCTs using multivariate regression models for the role of HLA mismatching on outcome. Median follow-up was 1841 days (IQR 909-2963). Mortality and GVHD increased with increasing numbers of HLA mismatches. A single HLA-B mismatch increased grade 3-4 acute GVHD (odds ratio [OR] 1·89, 95% CI 1·53-2·33; p<0·0001). Among the single HLA-B-mismatched transplantations, acute GVHD risk was higher with leader mismatching than with leader matching (OR 1·73, 1·02-2·94; p=0·042 for grade 2-4) and with an M leader shared allotype compared with a T leader shared allotype (OR 1·98, 1·39-2·81; p=0·0001 for grade 3-4). The preferred HLA-B-mismatched donor is leader-matched and shares a T leader allotype. The majority (1 836 939 [91·6%]) of the 2 004 742 US registry donors have the TT or MT genotype. INTERPRETATION: The HLA-B leader informs GVHD risk after HLA-B-mismatched unrelated HCT and differentiates high-risk HLA-B mismatches from those with lower risk. The leader of the matched allotype could be considered to be as important as the leader of the mismatched allotype for GVHD. Prospective identification of leader-matched donors is feasible for most patients in need of a HCT, and could lower GVHD and increase availability of HCT therapy. These findings are being independently validated and warrant further research in prospective trials. FUNDING: The National Institutes of Health, USA.
Authors: Sarah Cooley; Daniel J Weisdorf; Lisbeth A Guethlein; John P Klein; Tao Wang; Chap T Le; Steven G E Marsh; Daniel Geraghty; Stephen Spellman; Michael D Haagenson; Martha Ladner; Elizabeth Trachtenberg; Peter Parham; Jeffrey S Miller Journal: Blood Date: 2010-06-25 Impact factor: 22.113
Authors: Amir Horowitz; Zakia Djaoud; Neda Nemat-Gorgani; Jeroen Blokhuis; Hugo G Hilton; Vivien Béziat; Karl-Johan Malmberg; Paul J Norman; Lisbeth A Guethlein; Peter Parham Journal: Sci Immunol Date: 2016-09-09
Authors: Aimee M Merino; Wei Song; Dongning He; Joseph Mulenga; Susan Allen; Eric Hunter; Jianming Tang; Richard A Kaslow Journal: J Infect Dis Date: 2012-04-05 Impact factor: 5.226
Authors: Monika Enqvist; Gustav Nilsonne; Oscar Hammarfjord; Robert P A Wallin; Niklas K Björkström; Mikael Björnstedt; Anders Hjerpe; Hans-Gustaf Ljunggren; Katalin Dobra; Karl-Johan Malmberg; Mattias Carlsten Journal: J Immunol Date: 2011-09-02 Impact factor: 5.422
Authors: Effie W Petersdorf; Theodore A Gooley; Mari Malkki; Andrea P Bacigalupo; Anne Cesbron; Ernette Du Toit; Gerhard Ehninger; Torstein Egeland; Gottfried F Fischer; Thibaut Gervais; Michael D Haagenson; Mary M Horowitz; Katharine Hsu; Pavel Jindra; Alejandro Madrigal; Machteld Oudshoorn; Olle Ringdén; Marlis L Schroeder; Stephen R Spellman; Jean-Marie Tiercy; Andrea Velardi; Campbell S Witt; Colm O'Huigin; Richard Apps; Mary Carrington Journal: Blood Date: 2014-10-16 Impact factor: 22.113
Authors: Veron Ramsuran; Vivek Naranbhai; Amir Horowitz; Ying Qi; Maureen P Martin; Yuko Yuki; Xiaojiang Gao; Victoria Walker-Sperling; Gregory Q Del Prete; Douglas K Schneider; Jeffrey D Lifson; Jacques Fellay; Steven G Deeks; Jeffrey N Martin; James J Goedert; Steven M Wolinsky; Nelson L Michael; Gregory D Kirk; Susan Buchbinder; David Haas; Thumbi Ndung'u; Philip Goulder; Peter Parham; Bruce D Walker; Jonathan M Carlson; Mary Carrington Journal: Science Date: 2018-01-04 Impact factor: 47.728
Authors: Yasuo Morishima; Satoko Morishima; Phil Stevenson; Yoshihisa Kodera; Mary Horowitz; Caroline McKallor; Mari Malkki; Stephen R Spellman; Ted Gooley; Effie W Petersdorf Journal: Transplant Cell Ther Date: 2022-04-08
Authors: Effie W Petersdorf; Mats Bengtsson; Mary Horowitz; Caroline McKallor; Stephen R Spellman; Eric Spierings; Ted A Gooley; Phil Stevenson Journal: Blood Date: 2022-05-19 Impact factor: 25.476
Authors: Ephraim J Fuchs; Shannon R McCurdy; Scott R Solomon; Tao Wang; Megan R Herr; Dipenkumar Modi; Michael R Grunwald; Taiga Nishihori; Michelle Kuxhausen; Stephanie Fingerson; Caroline McKallor; Asad Bashey; Yvette L Kasamon; Yung-Tsi Bolon; Ayman Saad; Joseph McGuirk; Sophie Paczesny; Shahinaz M Gadalla; Steven G E Marsh; Bronwen E Shaw; Stephen R Spellman; Stephanie J Lee; Effie W Petersdorf Journal: Blood Date: 2022-03-10 Impact factor: 25.476
Authors: Norman Shreeve; Delphine Depierreux; Delia Hawkes; James A Traherne; Ulla Sovio; Oisin Huhn; Jyothi Jayaraman; Amir Horowitz; Hormas Ghadially; John R B Perry; Ashley Moffett; John G Sled; Andrew M Sharkey; Francesco Colucci Journal: Immunity Date: 2021-04-21 Impact factor: 31.745
Authors: Effie W Petersdorf; Philip Stevenson; Mats Bengtsson; Dianne De Santis; Valerie Dubois; Ted Gooley; Mary Horowitz; Katharine Hsu; J Alejandro Madrigal; Mari Malkki; Caroline McKallor; Yasuo Morishima; Machteld Oudshoorn; Stephen R Spellman; Jean Villard; Mary Carrington Journal: Blood Date: 2020-07-16 Impact factor: 25.476